Highly Selective MMP-12 Antibodies

Tech ID: 32920 / UC Case 2021-801-0


Matrix metalloproteinase-12 (MMP-12), is a member of a family of potent inflammatory mediators and therefore an important pharmacological target. It’s role in the pathogenesis of diseases like chronic obstructive pulmonary disease, emphysema, and asthma is well established.  Studies have also shown MMP-12 contributes to the pathogenesis of neurological diseases like stroke, spinal cord injury, and multiple sclerosis.  Highly specific MMP-12 inhibitors are desirable to treat the diseases described in this paragraph since broad spectrum MMP inhibitors in the past have failed clinical trials due to their off-target effects.

Brief Description

Researchers from the University of California, Riverside have developed potent monoclonal antibody inhibitors with high MMP-12 selectivity.  These antibodies have applications in pharmaceuticals and biomedical sciences. Specifically, these antibodies may be developed as  therapies for inflammatory and neurological diseases.


Fig 1: Inhibitory function of the MMP-12 antibodies LG4, LH6, and LH11 towards cdMMP-12. 


  • A potential therapy for inflammatory and neurological diseases.

Patent Status

Patent Pending

Related Materials


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


protease inhibitor, MMP-12, antibody, stroke, inflammation, neurological

Categorized As